Abstract
The c-myc oncogene has been extensively implicated in cell proliferation, cell differentiation and programmed cell death. Aberrant expression of the c-myc gene product has been observed in a range of tumours and has also been implicated in cisplatin (cis-dichlorodiammineplatinum)-mediated chemoresistance. A solid transplantable tumour model in syngeneic DA rats was subjected to treatment with cisplatin to determine the impact of such therapy on endogenous c-myc gene expression. Serially transplanted tumours were intravenously treated with a single cisplatin dose (1 mg/kg) and c-myc expression analysed 2 and 7 days after treatment. The surviving tumour cells display a significant 2-fold elevation in c-myc expression at 48 h and 7 days after treatment. Primary cell cultures have been derived from untreated in vivo tumours of the same model and subjected to treatment with a c-myc phosphorothioate antisense oligomer. Administration of 5 microM c-myc antisense oligomer directed at the initiation codon and first four codons of c-myc mRNA results in total inhibition of c-myc expression and coincident suspension of cell growth for a period of 4 days in culture. Antisense therapies directed at the c-myc gene may well prove an effective tool for treating tumours in conjunction with cisplatin as these findings show that tumour cells surviving cisplatin chemotherapy display elevated c-myc expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Walker, T., White, J., Esdale, W. et al. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 73, 610–614 (1996). https://doi.org/10.1038/bjc.1996.105
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.105
This article is cited by
-
miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
Oncogene (2019)
-
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma
Cell Death & Disease (2019)
-
Transformation of follicular lymphoma to double-hit lymphoma during adjuvant chemotherapy for concurrent ovarian carcinoma
International Journal of Hematology (2019)
-
TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer
Scientific Reports (2017)
-
Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient mice
Cancer Chemotherapy and Pharmacology (2013)